Type to search



New aquaculture alliance set to develop precision dosing solutions

Aquaculture disease management and dynamic dosing expert Aqua Pharma are joining forces with microbial fingerprinting experts KYTOS to develop SEATRUTM – a unique new service platform offering shrimp farmers worldwide effective microbial control through precise dosing recommendations.

The initiative is set to start next month (July 2022) with a two-year research project based in Indonesia with local partner eFishery, the world’s largest aquaculture tech start-up.

Markus Wu, Head of Office Indonesia for Solvay and Aqua Pharma at Aqua Pharma Group, said: “Our priority at Aqua Pharma is to provide disease prevention and control systems to the aquaculture industry with fish and shrimp welfare at the forefront. We are delighted to have teamed up with KYTOS to further develop SEATRUTM   – a tool which will use the power of KYTOS technology to read the aquaculture microbiome of farms, anticipating and reducing disease thanks to individually tailored and precise dosing of eco-friendly health management solutions.

“Shrimp farmers are currently hampered by a lack of reliable data on water quality and animal health, resulting in frequent unpredictable disease outbreaks. SEATRUTM  will allow farmers to adopt a preventative management approach, using best-in-class products like Aqualisan® to increase production, sustainability and profitability.”

“Disease prevention is the number one challenge facing shrimp aquaculture today.  With disease able to completely wipe out a pond in five days the sector urgently needs effective preventative methods.  Innovative new pond reading technologies combined with eco-friendly products like Aqualisan® for shrimp pond management have huge potential to improve the welfare of the shrimp and the profitability of the sector.”

According to WWF*, over 55% of the shrimp consumed worldwide is farmed, with a market growth of 8% over the past decade.  The annual loss to the shrimp industry as a result of disease is estimated at $6 billion per year.

The research project is due to run from July 2022 until mid-2024, after which commercial scaling will follow.